Skip to main content

Chinook Therapeutics, Inc. (KDNY)

NASDAQ: KDNY · Delayed Price · USD
12.89 -0.12 (-0.92%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap606.63M
Revenue (ttm)-18.31M
Net Income (ttm)-137.22M
Shares Out43.86M
EPS (ttm)-4.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume233,847
Open12.98
Previous Close13.01
Day's Range12.82 - 13.15
52-Week Range10.95 - 21.68
Betan/a
AnalystsStrong Buy
Price Target32.71 (+153.8%)
Est. Earnings DateNov 4, 2021

About KDNY

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatme...

IndustryBiotechnology
CEOStephen Isaacs
Employees105
Stock ExchangeNASDAQ
Ticker SymbolKDNY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for KDNY stock is "Strong Buy." The 12-month stock price forecast is 32.71, which is an increase of 153.76% from the latest price.

Price Target
$32.71
(153.76% upside)
Analyst Consensus: Strong Buy

News

Chinook Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

3 weeks ago - GlobeNewsWire

Chinook Therapeutics (KDNY) Reports Q2 Loss, Lags Revenue Estimates

Chinook (KDNY) delivered earnings and revenue surprises of 10.53% and -86.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Chinook Therapeutics (KDNY) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Chinook (KDNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021

SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...

2 months ago - GlobeNewsWire

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...

2 months ago - GlobeNewsWire

New Strong Sell Stocks for June 25th

CVGW, KDNY, CMTL, GPL and TVTX have been added to the Zacks Rank #5 (Strong Sell) List on June 25, 2021.

Other symbols:CMTLCVGWGPLTVTX
2 months ago - Zacks Investment Research

Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., t...

SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision ...

3 months ago - GlobeNewsWire

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ER...

SEATTLE, June 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision ...

3 months ago - GlobeNewsWire

Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Cong...

SEATTLE, May 25, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

3 months ago - GlobeNewsWire

Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

SEATTLE, May 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

4 months ago - GlobeNewsWire

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

4 months ago - GlobeNewsWire

Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021

SEATTLE, April 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

5 months ago - GlobeNewsWire

Chinook Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

5 months ago - GlobeNewsWire

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

5 months ago - GlobeNewsWire

Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glom...

Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022

5 months ago - GlobeNewsWire

Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger

Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs

5 months ago - GlobeNewsWire

Chinook (KDNY) Surges 7%: Is This an Indication of Further Gains?

Chinook (KDNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

5 months ago - Zacks Investment Research

Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA...

VANCOUVER, British Columbia and SEATTLE, March 30, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercializa...

5 months ago - GlobeNewsWire

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with ...

Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021

6 months ago - GlobeNewsWire

Will Chinook Therapeutics (KDNY) Report Negative Q4 Earnings? What You Should Know

Chinook (KDNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines fo...

VANCOUVER, British Columbia and SEATTLE, March 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY) and Evotec SE today announced a strategic collaboration focused on the discovery and...

6 months ago - GlobeNewsWire

Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies

Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE (OTCMKTS: EVTCY) have collaborated for the discovery and development of precision medicine therapies for patients with chronic kidney diseases (CKD)...

6 months ago - Benzinga

Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit

Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials

7 months ago - GlobeNewsWire

Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

VANCOUVER, British Columbia and SEATTLE, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercializat...

7 months ago - GlobeNewsWire

Chinook Therapeutics Nabs Rare Pediatric Disease Tag For CHK-336 In Primary Hyperoxaluria

The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Inc's (NASDAQ: KDNY) CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxalu...

7 months ago - Benzinga